Clinical outcomes of systemic chemotherapy in hepatocellular carcinoma patients with multiple lung metastases

Ki Tae Yoon, Jong Won Choi, Junyong Park, SangHoon Ahn, Yong Han Paik, Kwan Sik Lee, KwangHyub Han, Chae Yoon Chon, doyoung kim

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

BACKGROUND/AIMS: Advanced hepatocellular carcinoma (HCC) with multiple lung metastases has a poor prognosis with no effective treatment having been established. This study evaluated the outcomes of systemic chemotherapy for advanced HCC with multiple lung metastases. METHODS: Between January 2000 and December 2006, 68 patients were diagnosed with HCC presenting with multiple lung metastases. Sixteen patients in the terminal stage, such as Child-Pugh grade ;C' or an Eastern Cooperative Oncology Group performance status exceeding grade 2, were excluded from the analysis. The following treatment modalities were applied: 26 patients received primary tumor treatment (transarterial chemoembolization or intra-arterial chemotherapy) with systemic chemotherapy, 10 patients received primary treatment only, 8 patients received systemic chemotherapy only, and 8 patients received highly supportive care. The treatment responses and median survival times for the modalities were analyzed and compared. RESULTS: The median age of the 52 analyzed patients (45 males) was 52.4 years. The most common etiology of HCC was chronic hepatitis B virus infection (n=44, 84.6%) followed by hepatitis C virus infection (n=2, 3.8%), with the etiology being unknown in 6 cases (11.5%). The treatment modality had no significant effect on the treatment response rate (P=0.432) or median survival time (133, 66, 74, and 96 days for primary tumor treatment with systemic chemotherapy, primary tumor treatment only, systemic chemotherapy only, and highly supportive care, respectively; P=0.067). CONCLUSIONS: We found that systemic chemotherapy was not effective in treating HCC presenting with multiple lung metastases. Improving the effectiveness of systemic treatment and selecting patients who would benefit from such treatment remains a major challenge.

Original languageEnglish
Pages (from-to)360-370
Number of pages11
JournalThe Korean journal of hepatology
Volume14
Issue number3
DOIs
Publication statusPublished - 2008 Jan 1

Fingerprint

Hepatocellular Carcinoma
Neoplasm Metastasis
Drug Therapy
Lung
Therapeutics
Virus Diseases
Neoplasms
Survival
Chronic Hepatitis B
Hepatitis B virus
Hepacivirus
Outcome Assessment (Health Care)

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

@article{8d18c8620b534d698bb265d19560932a,
title = "Clinical outcomes of systemic chemotherapy in hepatocellular carcinoma patients with multiple lung metastases",
abstract = "BACKGROUND/AIMS: Advanced hepatocellular carcinoma (HCC) with multiple lung metastases has a poor prognosis with no effective treatment having been established. This study evaluated the outcomes of systemic chemotherapy for advanced HCC with multiple lung metastases. METHODS: Between January 2000 and December 2006, 68 patients were diagnosed with HCC presenting with multiple lung metastases. Sixteen patients in the terminal stage, such as Child-Pugh grade ;C' or an Eastern Cooperative Oncology Group performance status exceeding grade 2, were excluded from the analysis. The following treatment modalities were applied: 26 patients received primary tumor treatment (transarterial chemoembolization or intra-arterial chemotherapy) with systemic chemotherapy, 10 patients received primary treatment only, 8 patients received systemic chemotherapy only, and 8 patients received highly supportive care. The treatment responses and median survival times for the modalities were analyzed and compared. RESULTS: The median age of the 52 analyzed patients (45 males) was 52.4 years. The most common etiology of HCC was chronic hepatitis B virus infection (n=44, 84.6{\%}) followed by hepatitis C virus infection (n=2, 3.8{\%}), with the etiology being unknown in 6 cases (11.5{\%}). The treatment modality had no significant effect on the treatment response rate (P=0.432) or median survival time (133, 66, 74, and 96 days for primary tumor treatment with systemic chemotherapy, primary tumor treatment only, systemic chemotherapy only, and highly supportive care, respectively; P=0.067). CONCLUSIONS: We found that systemic chemotherapy was not effective in treating HCC presenting with multiple lung metastases. Improving the effectiveness of systemic treatment and selecting patients who would benefit from such treatment remains a major challenge.",
author = "Yoon, {Ki Tae} and Choi, {Jong Won} and Junyong Park and SangHoon Ahn and Paik, {Yong Han} and Lee, {Kwan Sik} and KwangHyub Han and Chon, {Chae Yoon} and doyoung kim",
year = "2008",
month = "1",
day = "1",
doi = "10.3350/kjhep.2008.14.3.360",
language = "English",
volume = "14",
pages = "360--370",
journal = "Clinical and molecular hepatology",
issn = "2287-2728",
publisher = "Korean Association for the Study of the Liver",
number = "3",

}

Clinical outcomes of systemic chemotherapy in hepatocellular carcinoma patients with multiple lung metastases. / Yoon, Ki Tae; Choi, Jong Won; Park, Junyong; Ahn, SangHoon; Paik, Yong Han; Lee, Kwan Sik; Han, KwangHyub; Chon, Chae Yoon; kim, doyoung.

In: The Korean journal of hepatology, Vol. 14, No. 3, 01.01.2008, p. 360-370.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Clinical outcomes of systemic chemotherapy in hepatocellular carcinoma patients with multiple lung metastases

AU - Yoon, Ki Tae

AU - Choi, Jong Won

AU - Park, Junyong

AU - Ahn, SangHoon

AU - Paik, Yong Han

AU - Lee, Kwan Sik

AU - Han, KwangHyub

AU - Chon, Chae Yoon

AU - kim, doyoung

PY - 2008/1/1

Y1 - 2008/1/1

N2 - BACKGROUND/AIMS: Advanced hepatocellular carcinoma (HCC) with multiple lung metastases has a poor prognosis with no effective treatment having been established. This study evaluated the outcomes of systemic chemotherapy for advanced HCC with multiple lung metastases. METHODS: Between January 2000 and December 2006, 68 patients were diagnosed with HCC presenting with multiple lung metastases. Sixteen patients in the terminal stage, such as Child-Pugh grade ;C' or an Eastern Cooperative Oncology Group performance status exceeding grade 2, were excluded from the analysis. The following treatment modalities were applied: 26 patients received primary tumor treatment (transarterial chemoembolization or intra-arterial chemotherapy) with systemic chemotherapy, 10 patients received primary treatment only, 8 patients received systemic chemotherapy only, and 8 patients received highly supportive care. The treatment responses and median survival times for the modalities were analyzed and compared. RESULTS: The median age of the 52 analyzed patients (45 males) was 52.4 years. The most common etiology of HCC was chronic hepatitis B virus infection (n=44, 84.6%) followed by hepatitis C virus infection (n=2, 3.8%), with the etiology being unknown in 6 cases (11.5%). The treatment modality had no significant effect on the treatment response rate (P=0.432) or median survival time (133, 66, 74, and 96 days for primary tumor treatment with systemic chemotherapy, primary tumor treatment only, systemic chemotherapy only, and highly supportive care, respectively; P=0.067). CONCLUSIONS: We found that systemic chemotherapy was not effective in treating HCC presenting with multiple lung metastases. Improving the effectiveness of systemic treatment and selecting patients who would benefit from such treatment remains a major challenge.

AB - BACKGROUND/AIMS: Advanced hepatocellular carcinoma (HCC) with multiple lung metastases has a poor prognosis with no effective treatment having been established. This study evaluated the outcomes of systemic chemotherapy for advanced HCC with multiple lung metastases. METHODS: Between January 2000 and December 2006, 68 patients were diagnosed with HCC presenting with multiple lung metastases. Sixteen patients in the terminal stage, such as Child-Pugh grade ;C' or an Eastern Cooperative Oncology Group performance status exceeding grade 2, were excluded from the analysis. The following treatment modalities were applied: 26 patients received primary tumor treatment (transarterial chemoembolization or intra-arterial chemotherapy) with systemic chemotherapy, 10 patients received primary treatment only, 8 patients received systemic chemotherapy only, and 8 patients received highly supportive care. The treatment responses and median survival times for the modalities were analyzed and compared. RESULTS: The median age of the 52 analyzed patients (45 males) was 52.4 years. The most common etiology of HCC was chronic hepatitis B virus infection (n=44, 84.6%) followed by hepatitis C virus infection (n=2, 3.8%), with the etiology being unknown in 6 cases (11.5%). The treatment modality had no significant effect on the treatment response rate (P=0.432) or median survival time (133, 66, 74, and 96 days for primary tumor treatment with systemic chemotherapy, primary tumor treatment only, systemic chemotherapy only, and highly supportive care, respectively; P=0.067). CONCLUSIONS: We found that systemic chemotherapy was not effective in treating HCC presenting with multiple lung metastases. Improving the effectiveness of systemic treatment and selecting patients who would benefit from such treatment remains a major challenge.

UR - http://www.scopus.com/inward/record.url?scp=58149352914&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149352914&partnerID=8YFLogxK

U2 - 10.3350/kjhep.2008.14.3.360

DO - 10.3350/kjhep.2008.14.3.360

M3 - Article

C2 - 18815459

AN - SCOPUS:58149352914

VL - 14

SP - 360

EP - 370

JO - Clinical and molecular hepatology

JF - Clinical and molecular hepatology

SN - 2287-2728

IS - 3

ER -